GlassScriptPhysician profile
Michael A Regan
NPI 1831575687
$10,085.84
in general payments reported to CMS, 2019-2025
28 companies · $3,446 in 2025
The $3,446 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $1,038 · 2023: $2,491 · 2024: $2,561 · 2025: $3,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,246 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,245.74 |
| Education | $252.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,342.79 | 2022-2025 | |
| Abbvie INC. | $1,309.28 | 2021-2025 | |
| Pfizer INC. | $893.09 | 2021-2025 | |
| Janssen Biotech, INC. | $790.40 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $585.95 | 2022-2025 | Aklief, Oracea, Nemluvio |
| Sun Pharmaceutical Industries INC. | $516.59 | 2021-2025 | Winlevi, Ilumya |
| Mayne Pharma Commercial LLC | $498.43 | 2023-2025 | |
| Leo Pharma INC. | $460.90 | 2021-2025 | Adbry, Anzupgo |
| Incyte Corporation | $454.06 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $447.41 | 2021-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $410.86 | 2024-2025 | Zoryve |
| Genzyme Corporation | $334.30 | 2021-2025 | |
| Ucb, INC. | $332.71 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $302.92 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $286.65 | 2022-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $215.81 | 2023-2024 | Sotyktu |
| Dermavant Sciences, INC. | $215.31 | 2023-2024 | Vtama |
| Organon LLC | $213.38 | 2023-2025 | Vtama, Hadlima |
| Almirall LLC | $135.89 | 2023 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.62 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Epi Health, LLC | $54.53 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.11 | 2023-2024 | Spevigo |
| Blueprint Medicines Corporation | $44.00 | 2023 | Ayvakit |
| Journey Medical Corporation | $30.84 | 2025 | |
| Vyne Pharmaceuticals INC. | $26.05 | 2021 | |
| Cipher Pharmaceuticals US LLC | $18.24 | 2025 | Spinosad, Natroba |
| Verrica Pharmaceuticals INC. | $17.16 | 2025 | Ycanth |
| Lnhc, INC | $13.56 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Regan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.